Prevention and management of complications after stroke is an integral component of stroke treatment.^[@R1]^ Infectious complications after intracerebral hemorrhage (ICH) have been identified as a marker of poor clinical condition, and as such are believed to be a significant contributor to post-ICH death and disability.^[@R2]^ In addition to infections, inflammatory responses have been associated with poor poststroke outcomes. One such inflammatory response, systemic inflammatory response syndrome (SIRS), is characterized by the presence of 2 or more of the following: hyperthermia or hypothermia, leukopenia or leukocytosis, tachycardia, or tachypnea and is believed to be a systemic reaction to a stimulus (e.g., trauma and surgery).^[@R3]^ SIRS has been recognized in nonneurologic illnesses, as well as in ischemic stroke, and patients with subarachnoid hemorrhage as a risk factor for poor outcomes.^[@R4][@R5][@R6]^ In addition, a relationship between SIRS and stroke severity has been identified in patients with ICH and subarachnoid hemorrhage,^[@R6]^ as well as with stroke severity and infarct volume in patients with ischemic stroke.^[@R7]^ Although prior work has demonstrated a relationship between SIRS and functional outcomes, independent of infection, only 1 single-center study has investigated the role of SIRS on the ICH outcome in the absence of an infection.^[@R8]^ SIRS on admission has also been associated with persistent SIRS during an ICH hospitalization in a single-center study, but no study has yet assessed the effect of SIRS identified at the time of admission on stroke outcomes at discharge or later in patients with ICH. The presence of SIRS in patients with ICH at hospital admission was hypothesized to be related to increased risk of poor outcomes at discharge and 3 months.

METHODS {#s1}
=======

The Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) study is a prospective, multicenter study of ICH among white, black, and Hispanic patients. The ERICH study comprised 19 recruitment centers throughout the United States, and the methods have been published previously.^[@R2]^ Recruitment periods varied by recruitment center, with enrollment ranging from September 2010 through October 2015. Patients were enrolled in the study if they had spontaneous ICH, were ≥18 years of age, lived within 75 miles of one of the recruitment centers, identified as non-Hispanic white, non-Hispanic black, or Hispanic, and provided informed consent, either through their own volition or through a legal representative.

ICH was defined as a nontraumatic, spontaneous focal blood collection within the brain parenchyma (including peripartum and anticoagulation-associated ICH) seen on neuroimaging with an abrupt onset of severe headache, altered level of consciousness, or focal neurologic deficit.^[@R9],[@R10]^ Cases of ICH due to hemorrhagic conversion of a recent ischemic stroke, malignancy-associated coagulopathy, dural venous sinus thrombosis, vascular malformations, aneurysms, or tumors were excluded. Patients were excluded from the present analysis if they died within 72 hours of admission, if they were missing information preventing the assessment of SIRS on admission, and if there was no information on the discharge outcome. A sensitivity analysis was conducted including the patients who died within 72 hours of admission.

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

The study was approved by the institutional review boards at the participating centers. Eligible participants were approached for informed consent to participate in this study.

Data collection and variable definition. {#s1-2}
----------------------------------------

Demographic and clinical data collected on the case report forms at each center included medical history, imaging, and laboratory data. The central imaging core determined the ICH location and volume, as well as the presence of intraventricular hemorrhage (IVH). ICH locations were categorized as brainstem, cerebellum, deep, lobar, and primary IVH. In the adjusted analyses, the ICH location was recategorized as lobar vs. all others (brainstem, cerebellum, deep, and primary IVH). ICH scores were calculated for each patient as a measure of stroke severity, with points assigned for age 80 or older, Glasgow Coma Scale (GCS) at presentation, ICH volume greater than 30 mL, presence of IVH, and infratentorial origin of hemorrhage.^[@R9]^ In adjusted models, the location was divided into lobar vs nonlobar.

The presence of SIRS was defined as having 2 or more of the following (per standard criteria): (1) heart rate greater than 90 beats per minute, (2) respiratory rate greater than 20 breaths per minute, (3) white blood cell count less than 4,000/mm^3^ or greater than 12,000/mm^3^ or more than 10% of polymorphonuclear leukocytes, or (4) body temperature less than 36°C or greater than 38°C.^[@R3],[@R10]^ For the present analysis, the SIRS status was based on vital sign and laboratory data at the time of hospital admission for ICH. Case report forms did not record vital sign and laboratory information after admission; therefore, SIRS that may have developed during the hospital stay could not be determined. SIRS was considered present if 2 or more of the necessary criteria were met on admission. This was a more transient definition without a strict timeframe criterion that has been used in prior research. In-hospital treatments and infections were documented. Infections were identified throughout the entire hospital stay from the medical records, and they were reported on the chart abstraction form. Infections were defined as a diagnosis of infection any time during the hospital stay that was noted in the medical record with categories including respiratory, urinary, bloodstream, ventriculitis, and other.

The primary outcome was poor functional outcome at discharge and 3 months, defined as a modified Rankin Scale (mRS) score of 3--6.^[@R11]^

Statistical analyses. {#s1-3}
---------------------

The χ^2^ test of independence was used to assess baseline demographic differences between patients with SIRS and those without SIRS for categorical variables, and the Wilcoxon rank sum test was used for continuous variables. Odds ratios (ORs) and 95% confidence intervals (CIs) (OR, 95% CI) were calculated for crude and adjusted logistic regression models to estimate the odds of poor outcomes for patients with SIRS. No adjustments were made for multiple comparisons, as this was an exploratory analysis.^[@R12]^ Additional analyses were conducted to assess the relationship among infection, SIRS, and SIRS plus infection on the outcomes of interest and to explore the associations in those with less severe strokes and premorbid disability. An alpha of 0.05 was set as the level of significance.

RESULTS {#s2}
=======

Of 2,997 ICH cases enrolled in the ERICH study before November 2015, 472 were excluded for unknown SIRS criteria because of missing data; 76 were excluded because of death within 72 hours of admission; and 8 were excluded for missing discharge outcome data, leaving 2,441 available for analysis. The majority of the patients with ICH were admitted within 24 hours of symptom onset (86.4%), with 8.4% of the patients with ICH admitted between 24 and 72 hours, and 5.2% of the patients admitted within 72 hours of symptom onset. Of the patients who met inclusion criteria, 343 (14.1%) met SIRS criteria on admission, of which 300 (87.5%) met only 2 criteria, 40 (11.7%) met 3 SIRS criteria, and 3 (0.9%) met all 4 SIRS criteria. Patients with ICH who had SIRS on admission were younger (58.2 vs 62.7 years; *p* \< 0.0001), had a higher initial ICH volume (25.4 vs 17.5 mL; *p* \< 0.0001), had a lower GCS score on admission (10.7 vs 13.1; *p* \< 0.0001), and different distributions in the hematoma location ([table 1](#T1){ref-type="table"}).

###### 

Descriptive characteristics of patients with SIRS on stroke admission and patients without SIRS on stroke admission
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Patients with SIRS on admission were at increased risk of infections identified during the hospital stay than patients without SIRS on admission (OR 2.01, 95% CI 1.59--2.54, *p* \< 0.0001). SIRS on admission remained a significant risk factor for infection during ICH admission after adjusting for race/ethnicity, hematoma volume and location, intubation, extraventricular drain (EVD) placement, dysphagia, percutaneous endoscopic gastrostomy (PEG) tube placement, and deep vein thrombosis (DVT) (OR 1.36, 95% CI 1.04--1.78, *p* = 0.0258). Restricting the analysis to patients who presented with an ICH score of 0--2 patients with SIRS on admission remained at increased risk of an infection during their ICH stay after adjusting for race/ethnicity, hematoma volume and location, intubation, EVD placement, dysphagia, PEG tube placement, and DVT (OR 1.54, 95% CI 1.12--2.11, *p* = 0.0079).

Patients with SIRS on admission were at increased risk of poor outcomes at both discharge (OR 1.96, 95% CI 1.42--2.70, *p* \< 0.0001) and 3 months (OR 1.75, 95% CI 1.35--2.33, *p* \< 0.0001). After adjusting for age, infections, IVH, hematoma volume and location, initial GCS, and preonset mRS, however, SIRS at admission no longer independently predicted outcomes ([table 2](#T2){ref-type="table"}). The relationship between SIRS and outcomes was primarily attenuated by adjustment for initial hematoma volume, GCS on admission, and presence of IVH. We conducted a stratified analysis in patients who had an ICH score of 0--2 on admission because of the extremely strong relationship between ICH score and outcomes. Similar to the entire sample, in the unadjusted analyses, SIRS on admission was related to poor functional outcomes at discharge (OR 1.61, 95% CI 1.14--2.28, *p* = 0.0067) and 3 months (OR 1.45, 95% CI 1.07--1.96, *p* = 0.0196), but this relationship did not persist after adjusting for age, infections, IVH, hematoma volume, hematoma location, initial GCS, and preonset mRS ([table 2](#T2){ref-type="table"}).

###### 

SIRS on admission and odds of poor functional outcomes after ICH
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An additional analysis limiting the sample to only patients who had a pre-ICH mRS of 0--2 was conducted because of concerns surrounding the relationship between pre-ICH morbidity and subsequent outcomes. SIRS on admission was related to both discharge (OR 2.00, 95% CI 1.45--2.78, *p* \< 0.0001) and 3-month poor functional outcomes (OR 1.78, 95% CI 1.35--2.32, *p* \< 0.0001) in the unadjusted analyses, but after adjusting for potential confounders, these relationships were no longer significant ([table 2](#T2){ref-type="table"}). In a sensitivity analysis that also included patients who died within 72 hours, the effect sizes did not change (table e-1 at [Neurology.org/nn](http://nn.neurology.org/lookup/doi/10.1212/NXI.0000000000000428)).

We further classified patients as (1) SIRS with infection, (2) SIRS only, (3) infection only, and (3) neither SIRS nor infection to assess the relationship between these categories and functional outcomes ([table 3](#T3){ref-type="table"}). Patients with both SIRS and infections (OR 4.55, 95% CI 2.04--10.0, *p* = 0.0002), as well as patients with only an infection (OR 3.45, 95% CI 2.38--5.00, *p* \< 0.0001) were at increased risk of poor functional outcomes at discharge after ICH after adjusting for age, IVH, hematoma volume and location (lobar vs nonlobar), and initial GCS. Patients with SIRS only were not at increased risk of poor functional outcomes at discharge after ICH (OR 1.07, 95% CI 0.69--1.67, *p* = 0.7452) after adjusting for age, IVH, ICH volume, location, and initial GCS. The associations remained at 3 months after adjusting for age, IVH, hematoma volume and location, and admission GCS ([table 3](#T3){ref-type="table"}). Restricting to patients who presented with an ICH score of 0--2, patients with both SIRS and infections (OR 3.49, 95% CI 2.38--5.00, *p* \< 0.0001), as well as patients with only infections (OR 4.35, 95% CI 2.00--10.0, *p* = 0.0002), were at increased risk of poor functional outcomes at discharge after adjusting for age, IVH, hematoma volume and location (lobar vs non-lobar), and initial GCS. In this restricted sample, patients with SIRS only were not at increased risk of poor functional outcomes at discharge after ICH (OR 1.06, 95% CI 0.68--1.67, *p* = 0.7790) after adjusting for age, IVH, hematoma volume and location, and admission GCS. These associations remained at 3 months, but the effect sizes were attenuated after adjusting for age, IVH, hematoma volume and location, and admission GCS ([table 3](#T3){ref-type="table"}).

###### 

SIRS on admission and odds of poor functional outcomes after ICH in patients who had a pre-ICH mRS of 0--2
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DISCUSSION {#s3}
==========

We found in a national, multicenter study among a racially and ethnically diverse population that SIRS was present on admission in ∼1 in 10 patients with ICH and that SIRS on admission was associated with stroke severity and infections during hospitalization, but it was not independently associated with outcomes at discharge and at 3 months after ICH. We found that patients with SIRS and an infection, or an infection only, were at an increased risk of poor functional outcomes at both discharge and 3 months, whereas SIRS in the absence of an infection was not related to outcomes.

Our study found that 14% of patients with ICH met SIRS criteria on admission. From this sample, the prevalence of SIRS on admission was lower than that reported for in-hospital SIRS in patients with acute ischemic stroke treated with tissue plasminogen activator (18%), patients with ICH (23%), and patients with subarachnoid hemorrhage (54%--86%).^[@R5],[@R6],[@R8]^ The lower prevalence in our population may reflect the fact that SIRS requires time to develop in patients with acute ICH or the need for a series of assessments over time to make a determination of SIRS.

The relationship between SIRS on admission and in-hospital infection may provide an insight into which patients with ICH are at the highest risk of an infection. The prevalence of infection in this study was consistent with prior research.^[@R13]^ Stroke severity,^[@R14]^ complications,^[@R15]^ and procedures^[@R16]^ have been consistently identified as risk factors for poststroke infection. Considering the relationship between SIRS on admission and stroke severity, the relationship between SIRS on admission and infection was not surprising. Furthermore, as shown in patients with trauma, SIRS on admission has been consistently identified as a significant predictor of infection but not outcomes,^[@R17]^ whereas persistent SIRS was a significant predictor of both infections and outcomes.^[@R18],[@R19]^ These findings suggest that SIRS on admission could be a simple way to identify patients with ICH at high risk of developing an infection.

Consistent with trauma, our study provides evidence that SIRS on admission is not independently related to functional outcomes at discharge after ICH. In-hospital SIRS, in contrast, was associated with poor functional outcomes at discharge in patients with ICH.^[@R8]^ In a single-center study, admission SIRS was a major predictor of in-hospital SIRS, but not independently associated with discharge functional outcomes. However, in-hospital SIRS was associated with poor discharge functional outcomes.^[@R8]^ We assessed the relationship between SIRS and infections on long-term outcomes and found that patients who had either SIRS plus an infection or only an infection were at increased risk of poor functional outcomes at discharge and 3 months. SIRS on admission in the absence of an infection was not associated with functional outcomes. Explanation for these discrepancies could be due to differences in the SIRS definition in each study. The strict definition of in-hospital SIRS requires a 24-hour period to meet criteria, so only patients with a sustained inflammatory response are identified as having in-hospital SIRS. Positive association between persistent in-hospital SIRS and poor ICH outcomes are more consistently found in stroke and trauma.^[@R8],[@R17],[@R18]^

More severe strokes are associated with the prevalence of SIRS, indicating that SIRS could be due to an inflammatory response from the stroke itself. The exact mechanism, however, is not well understood, with prior research suggesting that inflammation plays a role in the pathophysiology of tissue damage.^[@R20][@R21][@R23]^ After accounting for hematoma volume on admission, GCS on admission, and presence of IVH on admission, the relationship between SIRS on admission and outcomes was attenuated. This is consistent with prior work that highlighted a relationship between SIRS on admission and markers of stroke severity, but not an independent association with stroke outcomes.^[@R24]^

This study identified a strong relationship between SIRS on admission and stroke severity, as defined as ICH score. This finding supports previous research in acute ischemic stroke, ICH, and subarachnoid hemorrhage, where there were strong positive associations between stroke severity and identification of SIRS during hospitalization.^[@R25]^ These findings suggest that inflammation might be one mechanism by which stroke severity influences stroke outcomes. This was expected considering that individual components of SIRS criteria and stroke severity, hematoma growth, and hemorrhage volume have been linked in prior research.^[@R26][@R27][@R30]^

Identifying patients at increased risk of poor outcomes and subsequently treating the patient or reducing the risk of poor outcomes is of great clinical importance. However, there are no specific treatments for SIRS. Use of anti-inflammatory or immunosuppressive treatments for SIRS, or any type of poststroke inflammatory response, is complicated by the potential for an increased risk of infection with immunosuppression.^[@R31]^ In patients with both ischemic and hemorrhagic stroke, potential treatment options for poststroke inflammation include stem cells (by protecting neurons from immune cell--mediated apoptosis), therapeutic hypothermia, inhibition of microglial activation, minocycline, natalizumab, and fingolimod.^[@R32][@R33][@R37]^ Treating poststroke inflammation is further complicated by the beneficial role of the immune response after stroke, as the immune response can aid in stroke recovery.^[@R37]^ The utility of the immune response after stroke is believed to explain why identification of a consistent treatment for inflammation after stroke has not been identified.

This study has a number of limitations. The ERICH study was intended to assess the genetic risk factors for ICH. This analysis was not a prespecified aim of the ERICH study; thus, only baseline measures of vital signs are available, preventing the investigation of later development of SIRS during hospitalization. Testing for infection was performed only if clinical indications existed; thus, potential bias may exist for infection diagnosis. However, this bias is nondifferential and subsequently would bias our results toward the null. Furthermore, we did not have information on inflammatory biomarkers, such as C-reactive protein (CRP), at any time point. Further studies are needed to investigate the prognostic role of inflammatory biomarkers, such as CRP, in identifying inflammatory responses after an ICH. It is possible that CRP is a more sensitive and specific biomarker of inflammation than SIRS and could be a better indicator of the underlying infection.^[@R38][@R39][@R40]^ The advantage to a measure such as SIRS, however, is that it is widely available at no extra cost. ERICH was also designed to enroll an equal number of whites, blacks, and Hispanics, and as such, is not representative of the whole population. The in-hospital mortality rate is lower in the ERICH report (7.9%) than in prior reports, and the 90-day case fatality rate in this sample is 21.5%. The reduced case fatality rates at discharge and 90 days could influence the generalizability to only patients with ICH with milder strokes. Our study also has significant strengths, including a large, diverse population enrolled at a number of centers with experience in caring for patients with ICH. In addition, we were able to use a wealth of data on participants using information collected as part of the standard of care for patients with ICH.

SIRS on admission was identified in 14% of patients with ICH and was associated with stroke severity, infections, and outcomes. Accounting for stroke severity and other risk factors, SIRS on admission remained an independent risk factor for infectious complications in patients with ICH. After accounting for stroke severity and infections, SIRS on admission was no longer independently related to functional outcomes at discharge or 3 months.

Supplemental data at [Neurology.org/nn](http://nn.neurology.org/lookup/doi/10.1212/NXI.0000000000000428)
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